| Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer N Jin, A Bi, X Lan, J Xu, X Wang, Y Liu, T Wang, S Tang, H Zeng, Z Chen, ... Nature communications 10 (1), 2701, 2019 | 97 | 2019 |
| Design and synthesis of selective degraders of EGFRL858R/T790M mutant X Zhang, F Xu, L Tong, T Zhang, H Xie, X Lu, X Ren, K Ding European Journal of Medicinal Chemistry 192, 112199, 2020 | 78 | 2020 |
| A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer X Chen, C Yu, J Gao, H Zhu, B Cui, T Zhang, Y Zhou, Q Liu, H He, R Xiao, ... Theranostics 8 (9), 2348, 2018 | 56 | 2018 |
| Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy X Lu, T Zhang, SJ Zhu, Q Xun, L Tong, X Hu, Y Li, S Chan, Y Su, Y Sun, ... ACS medicinal chemistry letters 9 (11), 1123-1127, 2018 | 55 | 2018 |
| Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance T Zhang, R Qu, S Chan, M Lai, L Tong, F Feng, H Chen, T Song, P Song, ... Molecular cancer 19, 1-15, 2020 | 47 | 2020 |
| Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S Q Li, T Zhang, S Li, L Tong, J Li, Z Su, F Feng, D Sun, Y Tong, X Wang, ... ACS medicinal chemistry letters 10 (6), 869-873, 2019 | 47 | 2019 |
| Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFRL858R/T790M/C797S) J Shen, T Zhang, SJ Zhu, M Sun, L Tong, M Lai, R Zhang, W Xu, R Wu, ... Journal of Medicinal Chemistry 62 (15), 7302-7308, 2019 | 37 | 2019 |
| Design, synthesis, and biological evaluation of IRAK4-targeting PROTACs Y Chen, Y Ning, G Bai, L Tong, T Zhang, J Zhou, H Zhang, H Xie, J Ding, ... ACS medicinal chemistry letters 12 (1), 82-87, 2020 | 30 | 2020 |
| Discovery and structural optimization of N5-substituted 6, 7-dioxo-6, 7-dihydropteridines as potent and selective epidermal growth factor receptor (EGFR) inhibitors against … Y Hao, X Wang, T Zhang, D Sun, Y Tong, Y Xu, H Chen, L Tong, L Zhu, ... Journal of Medicinal Chemistry 59 (15), 7111-7124, 2016 | 26 | 2016 |
| Conformational Constrained 4-(1-Sulfonyl-3-indol) yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M … H Chen, M Lai, T Zhang, Y Chen, L Tong, S Zhu, Y Zhou, X Ren, J Ding, ... Journal of Medicinal Chemistry 65 (9), 6840-6858, 2022 | 23 | 2022 |
| LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo Y Liu, M Lai, S Li, Y Wang, F Feng, T Zhang, L Tong, M Zhang, H Chen, ... Cancer science 113 (2), 709-720, 2022 | 23 | 2022 |
| C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis Z Chen, L Tong, B Tang, H Liu, X Wang, T Zhang, X Cao, Y Chen, H Li, ... Acta Pharmacologica Sinica 40 (6), 823-832, 2019 | 21 | 2019 |
| Design and synthesis of Imidazo [1, 2-b] pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma Y Chen, G Bai, Y Ning, S Cai, T Zhang, P Song, J Zhou, W Duan, J Ding, ... European Journal of Medicinal Chemistry 190, 112092, 2020 | 19 | 2020 |
| DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo M Li, Y Lv, L Tong, T Peng, R Qu, T Zhang, Y Sun, Y Chen, L Wei, M Geng, ... Acta Pharmacologica Sinica 37 (3), 398-407, 2016 | 19 | 2016 |
| Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R YQ Liu, YN Wang, XY Lu, LJ Tong, Y Li, T Zhang, QJ Xun, F Feng, ... Acta Pharmacologica Sinica 39 (11), 1768-1776, 2018 | 13 | 2018 |
| 2-Oxo-3, 4-dihydropyrimido [4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant X Hu, Q Xun, T Zhang, SJ Zhu, Q Li, L Tong, M Lai, T Huang, CH Yun, ... Chinese Chemical Letters 31 (5), 1281-1287, 2020 | 12 | 2020 |
| Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants S Li, T Zhang, SJ Zhu, C Lei, M Lai, L Peng, L Tong, Z Pang, X Lu, J Ding, ... ACS Medicinal Chemistry Letters 13 (2), 196-202, 2022 | 11 | 2022 |
| Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors Q Tang, T Peng, J Hu, T Zhang, P Chen, D Chen, Y Wang, L Chen, ... European Journal of Medicinal Chemistry 233, 114249, 2022 | 8 | 2022 |
| Discovery of 1, 3‐Diaryl‐pyridones as Potent VEGFR‐2 Inhibitors: Design, Synthesis, and Biological Evaluation W Yan, Z Huang, Z Wang, S Cao, L Tong, T Zhang, C Wang, L Zhou, ... Chemical Biology & Drug Design 87 (5), 694-703, 2016 | 6 | 2016 |
| Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma Y Liu, Z Zhan, Z Kang, M Li, Y Lv, S Li, L Tong, F Feng, Y Li, M Zhang, ... Acta Pharmaceutica Sinica B, 2023 | 4 | 2023 |
